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Abstract 
Microparticles (MPs) are membrane fragments that may play a role in the pathogenesis of 
chronic respiratory diseases. We aimed to investigate whether human 
monocytes/macrophage-derived MPs could induce a pro-inflammatory phenotype in human 
bronchial smooth muscle cells (BSMC) and the effect of montelukast in this setting. 
Experimental methods included isolation of human monocytes/macrophages and generation 
of monocyte-derived MPs, RT-PCR analysis of gene expression, immunoenzymatic 
determination of pro-inflammatory factor release, bioluminescent assay of intracellular 
cAMP levels and electromobility shift assay analysis of NF-κB nuclear translocation. 
Stimulation of human BSMC with monocyte-derived MPs induced a pro-inflammatory 
switch in human BSMC by inducing gene expression (COX-2 and IL-8), protein release in the 
supernatant (PGE2 and IL-8), and heterologous β2-adrenoceptor desensitisation. The latter 
effect was most likely related to autocrine PGE2 since pre-treatment with COX inhibitors 
restored the ability of salbutamol to induce cAMP synthesis in desensitised cells. Challenge 
with MPs induced nuclear translocation of NF-κB and selective NF-κB inhibition decreased 
MP-induced cytokine release in the supernatant. Montelukast treatment prevented IL-8 
release and heterologous β2-adrenoceptor desensitisation in human BSMC exposed to 
monocyte-derived MPs by blocking NF-κB nuclear translocation. These findings provide 
evidence on the role of human monocyte-derived MPs in the airway smooth muscle 
phenotype switch as a novel potential mechanism in the progression of chronic respiratory 
diseases and on the protective effects by montelukast in this setting. 
 
 
 
Key words: microparticles, Montelukast, β2-agonists, airway smooth muscle cell, bronchial 
inflammation, cell signaling.
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1. Introduction 
The mononuclear phagocyte system is a key element in the complex inflammatory network 
that characterizes asthma and plays an important role in initiating the neutrophilic 
inflammatory response in patients with chronic obstructive pulmonary disease [1]. 
Microparticles (MPs) are membrane fragments shed by virtually all eukaryotic cells upon 
activation o during apoptosis that play a significant role in intercellular communication and 
also in several pathophysiological processes including coagulation and inflammation [2].  
We demonstrated that human monocyte/macrophage-derived MPs up-regulate 
inflammatory mediator synthesis by human airway epithelial cells [3,4] and elicit an 
autocrine activation loop by inducing superoxide anion production, cytokine release and NF-
κB activation [5]. However, it is unknown whether human airway smooth muscle plays a role 
in the pro-inflammatory action of monocyte/macrophage-derived MPs in the airways. This 
represents an interesting point to be investigated because this tissue has important synthetic 
functions and is a rich source of cytokines, chemokines, inflammatory mediators, and growth 
factors that contribute to the airway inflammation and remodeling [1].  
Montelukast (MK) is a potent cysteinyl leukotriene receptor (CysLTR) antagonist generally 
considered to have limited application in the therapy of asthma (i.e., exercise- and aspirin-
induced asthma and as add-on therapy in patients poorly controlled with inhaled 
corticosteroids, alone or in combination with β2-adrenoceptor agonists). Convincing 
evidence has emerged for the possible use of high-dose MK as anti-inflammatory agent in 
acute asthma [6]. The mechanisms by which MK can elicit these secondary CysLTRs-
independent effects have been recently reported [7] suggesting that this agent may have a 
broader spectrum of anti-inflammatory activities than originally thought.  
The present study was aimed at characterizing the pro-inflammatory profile of MPs in BSMC 
of human origin and the effect of montelukast in this experimental setting. We demonstrate 
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that human monocytes/macrophages shed MPs that can up-regulate the synthesis of pro-
inflammatory mediators by human airway smooth muscle cells and montelukast can reverse 
this phenotype. 
 
2. Materials and methods  
2.1 Generation of monocyte-derived MPs 
Human monocytes/macrophages (from which MPs were generated) were isolated from the 
buffy coats of blood donor by Ficoll gradient centrifugation followed by overnight culture of 
the mononuclear cell fraction. MPs generation was obtained from adherent cells stimulated 
with the calcium ionophore, A23187, as previously described [4]. Briefly, human monocytes 
(about 2 x 106 cells/well) were stimulated by the calcium ionophore A23187 at 12 µM in a 
final volume of 0.5 ml for 20 min at 37°C and the supernatant was recovered and cleared by 
centrifugation (14000 x g, 5 min, room temperature).  
MPs were characterized by multiparametric flow cytometry analysis (BD FACSCaliburTM 
Software; Becton Dickinson, San Jose, CA) of the monocyte markers CD14 and CD16, using a 
blend of fluorescent beads (Sigma-Aldrich, USA) of three diameters (0.1, 0.5 and 1 mm), to 
better identify the gate for MPs. In addition, according to Bardelli and co-workers [5], 
phosphatidylserine (PS) expression (about 2 nM) and Tissue Factor (TF) activity (9824 ± 
1700 A.U.; n= 6) were also evaluated.  
Human bronchial smooth muscle cells (BSMC; Lonza, Walkersville, MD, USA) were 
maintained exactly as recommended by the manufacturer in an optimized medium 
containing 5% fetal bovine serum, 5.5 mM glucose, 50 µg/ml gentamicin, 50 ng/ml 
amphotericin-B, 5 ng/ml insulin, 2 ng/ml basic fibroblast growth factor and 0.5 ng/ml 
epidermal growth factor (SmGM-2 Bullet Kit, Lonza).  
 
2.2 RT-PCR analysis 
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RNA from cells was extracted by using the RNeasy Mini kit and reverse-transcribed by the 
QuantiTect Reverse Transcription kit. PCR was performed by the Hot StartTaq Master Mix 
kit. Primers used were: 5‟-GCCTGACTCCTTCAAGATCG-3‟ (F) and 5‟-
AGGGACAGGTCTTGGTGTTG-3‟ (R), for COX-1; 5‟-TGAAACCCACTCCAAACACA-3‟ (F) and 
5‟-AACTGATGCGTGAAGTGCTG-3‟ (R) for COX-2; 5‟-ATGACTTCCAAGCTGGCCGT-3‟ (F) 
and 5‟-CCTCTTCAAAAACTTCTCCACACC-3‟ (R) for IL-8; 5‟-ACAAGGACGCCATCAACTG-3‟ 
(F) and 5‟-AAAGACCATAACCACCAAGGG-3‟ (R) for β2-adrenoceptor; 5‟-
GTGAAGGTCGGAGTCAACG-3‟ (F) and 5‟-GGTGAAGACGGCCAGTGGACTC-3‟ (R) for 
GAPDH and the expected amplification products were 446, 385, 285, and 300 bp long, 
respectively. Densitometric assay of RT-PCR bands was performed by using the „Quantity 
One‟ softhware (Bio-Rad Laboratories, Hercules, CA, USA). 
 
2.3 ELISA assays 
Soluble IL-8 expression was assessed in the conditioned medium of MP-stimulated BSMC 
with a sandwich ELISA (Hu IL-8 Cytoset, BioSource, Nivelles, Belgium) according to the 
manufacturers‟ instructions. 
 
2.4 cAMP assay 
Heterologous β2-adrenoceptor desensitisation was tested by exposing human BMSC to 
monocyte-derived MPs for 24 h. Intracellular cAMP levels were measured by the cAMP-
Glo™ Assay (Promega, Madison, WI, USA) in control and desensitised cells after stimulation 
with 10 μM salbutamol, in the presence or absence of Bay 11-7082 0.1-1 μM or montelukast 
30 μM for 24 h. BSMC were used between passages 4 and 8. 
 
2.5 Electrophoretic Mobility Shift Assay (EMSA) 
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Nuclear protein extracts was obtained by using the Nuclear extract Kit (Active Motif, CA, 
USA) and then incubated on ice with 32P-labelled PPAR oligonucleotide (Perkin Elmer Life 
Sciences, Boston, USA) in binding buffer. Consensus oligonucleotide for PPAR was 5‟-
CAAAACTAGGTCAAAGGTCA-3‟ (Santa Cruz Biotech, Santa Cruz, USA). DNA/protein 
complex was size fractionated on a non-denaturing 5% polyacrylamide gel in TBE buffer (100 
mM Tris-HCl, 100 mM boric acid, 2 mM EDTA) and detected by autoradiography. 
The activation of NF-kB induced by MPs was evaluated by measuring its nuclear migration 
(by electrophoretic mobility shift assay, EMSA), as previously described [5]. Nuclear extracts 
; obtained by using the Nuclear extract Kit, Active Motif, USA) from BSMC were 
incubated wit -dC) and [32P] ATP-labelled oligonucleotide probe (100,000-
150,000 cpm; Promega) in binding buffer (50% glycerol, 10 mM Tris-HCl, pH 7.6, 500 mM 
KCl, 10 mM EDTA, 1 mM dithiothreitol) for 30 min at room temperature. The NF-kB 
consensus oligonucleotide (5‟-AGTTGAGGGGACTTTCCCAGGC–3‟) was from Promega. The 
nucleotide-protein complex was separated on a 5 % polyacrylamide gel in 0.5 x TBE buffer 
(100 mM Tris-HCl, 100 mM boric acid, 2 mM EDTA) at 150 V on ice. The gel was dried and 
radioactive bands were detected by autoradiography [5]. Supershift assays were performed 
using 4 mg of commercial antibodies (anti-NF-kB p65: sc-8008 X from Santa Cruz Biotech, 
USA; anti-NF- NF-kB nuclear 
translocation was also performed, un-stimulated cells being = 1. 
 
 2.6 Data analysis and statistics 
All experiments were done in triplicate and data were expressed as mean ± SEM. Results 
were then plotted by Prism software (Graphpad Software, San Diego, CA, USA). Statistical 
analysis was carried out by one-way analysis of variance (ANOVA) followed by the Newman-
Keuls test for multiple comparisons.  
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3. Results 
3.1 Characterization of monocyte-derived MPs 
As reported in Figure 1, unstimulated monocytes are 98% CD14+ (Figure 1A). MPs generated 
from A23187-stimulated monocytes are 95% CD14+ and about 40% CD16+ (Figure 1B), so 
indicating the pro-inflammatory potential of the ionophore. As known, expression of the 
marker CD16 distinguishes two monocyte subsets [8]: CD14+/CD16+ monocytes, which 
release high amounts of pro-inflammatory cytokines, and CD14+/CD16- monocytes, which 
represent the “anti-inflammatory” subset, characterized by a poor cytokine release. 
 
3.2 Effect of MPs on the COX-2/prostanoid pathway 
Human BSMC were stimulated with monocyte-derived MPs over a period of 24 h to examine 
the effect of this potential pro-inflammatory stimulus on COX expression and release of 
PGE2 into the supernatant of cultured cells. A graphical summary of RT-PCR results is 
depicted in Figure 2A following densitometric analysis of COX-2 expression and 
normalization to the amount of GAPDH mRNA present in the samples. Specifically, a low 
expression level of 385 bp COX-2 transcript was identified in unstimulated cells, whereas 
treatment with isolated MPs significantly increased COX-2 mRNA levels (2.08±0.36-fold, as 
compared to control; p<0.05) without affecting COX-1 expression (Figure 2A). Noteworthy, 
such an effect was also accompanied by the release of PGE2 from BSMC into the culture 
medium (3.30±0.81-fold, as compared to control; p<0.01; Figure 2B).  
 
3.3 Effect of MPs on β2-adrenoceptor function 
Following MP stimulation, no effect was observed on the expression of β2-adrenoceptor gene 
transcription in BSMC (Figure 2A). Responsiveness to acute salbutamol at 10 μM was 
assessed in cells exposed to monocyte-derived MPs by measuring intracellular cAMP 
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synthesis. The ability of salbutamol to induce cAMP synthesis in unstimulated BSMC was 
reduced from 218±25 to 108±19 nM after treatment with MPs (p<0.01; Figure 2B).  
 
3.4 Role of the COX/PGE2 pathway in MP-induced β2-adrenoceptor hyporesponsiveness 
We next studied the effects of indomethacin (non-selective COX inhibitor) and NS398 
(selective COX-2 inhibitor) in this experimental setting to better characterise the role of COX 
enzymes on MP-induced β2-adrenoceptor desensitization in BSMC. Treatment with 
indomethacin or NS398 at 1 μM for 24 h completely restored salbutamol response in MP-
desensitized cells, at levels comparable to those obtained in unstimulated cells (Figures 3A 
and 3B). Noteworthy, heterologous β2-adrenoceptor desensitization was induced by treating 
unstimulated BSMC with exogenous PGE2 at a concentration similar to that released into the 
supernatant from MP-stimulated cells (i.e, 100 nM) (Figure 3C). 
 
3.5 Effect of MPs on the IL-8 expression 
The IL-8 mRNA levels were analysed by RT-PCR after 24 h of vehicle (control) or MPs and 
compared. A significant increase in IL-8 mRNA was induced by monocyte-derived MPs 
(Figure 4A). Unstimulated BSMC constitutively express an average of 350±66 pg/ml IL-8 
and overnight incubation with isolated MPs caused a 3-fold increase (1048±175 pg/ml; 
p<0.001) of the IL-8 release into the culture medium (Figure 4B).  
 
3.6 Role of NF-κB in MP-induced pro-inflammatory switch 
The selective inhibitor of NF-κB, Bay 11-7082, at 1 μM for 24 h, completely blocked the 
release of IL-8 (Figure 5A) and PGE2 (Figure 5B) in MP-stimulated BSMC without affecting 
cytokine synthesis in unstimulated cells. Bay 11-7082, at the concentrations used, did not 
affect cell viability assessed by WST-1 method (data not shown). 
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EMSA clearly demonstrated that challenge with MPs markedly increased nuclear 
translocation of NF-κB in BSMC (Figure 6; lanes 4-6) and the effect was quantified by 
densitometry (graph on the right). Experiments were performed in the presence of specific 
antibodies against p65 and p50 to confirm the specificity of the assay (see supershift of the 
protein-DNA complex and the relative densitometric analysis, respectively on the left and on 
the right of Figure 6). 
 
3.7 Effect of montelukast on MP-induced NF-κB nuclear translocation 
Montelukast 30 μM reduced translocation of the p50/p65 complex into the nucleus induced 
by MPs in BSMC, at levels comparable to those of unstimulated cells (Figure 6). MK, at the 
concentrations used, did not affect cell viability assessed by WST-1 method (data not shown). 
 
3.8 Effect of montelukast on MP-induced β2-adrenoceptor desensitization and IL-8 release 
Montelukast 30 μM restored salbutamol response in MP-desensitised cells at levels similar to 
those of controls, whereas drug alone did not significantly affect cAMP synthesis (Figure 7A).  
Montelukast significantly reduced the IL-8 release (p<0.01) from MP-stimulated cells 
without affecting the baseline IL-8 levels (Figure 7B).  
 
4. Discussion 
The cellular and molecular mechanisms that regulate the immunomodulatory functions of 
airway smooth muscle may offer new and important therapeutic targets in treating asthma 
and COPD. In line with evidence suggesting that human airway smooth muscle may secrete 
important factors that modulate submucosal airway inflammation [1,9], the findings of the 
present study suggest a potential novel mechanism that might contribute to initiate and 
perpetuate airway inflammation (Figure 8). Indeed, we demonstrate that human 
monocyte/macrophage-derived MPs activate important inflammatory pathways in BSMC 
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leading to a phenotype switch. Specifically, MPs increase the expression of COX-2 (but not 
COX-1) and the synthesis of PGE2 in human BSMC, a phenotype commonly observed 
following exposure of airway smooth muscle to proinflamatory stimuli [10]. This is most 
likely an autocrine and/or paracrine compensatory mechanism, because PGE2 is a potent 
bronchodilator and may also modulate the inflammatory milieu by inhibiting smooth muscle 
cell secretion of chemokines [11]. However, it should be noted that dysregulation of the PGE2 
synthesis/response axis was also observed in human pulmonary fibrotic diseases [12] and 
continuous stimulation by paracrine/autocrine PGE2 promotes heterologous β2-
adrenoceptor desensitisation in airway smooth muscle cells [13,14].  
Using inhibitors of cyclooxygenase, we found that β2-adrenoceptor desensitization was 
mediated through BSMC derived COX-2 induced prostaglandins suggesting that activation of 
the COX-2/prostanoid pathway by human monocyte/macrophages-derived MPs might 
promote bronchomotor tone dysregulation and altered response to β2-adrenoceptor agonists 
(Figure 8), a phenotype observed in patients with chronic respiratory diseases who do not 
adequately respond to this type of drugs (e.g., those with severe asthma and COPD). 
Noteworthy, autocrine prostaglandin production as potential mechanism of airway smooth 
muscle β2-adrenoceptor desensitization, has been recently proposed in rhinovirus infected 
bronchial epithelial cells [15].  
Elevated levels of IL-8 were found in the airway of patients with cystic fibrosis and asthma 
[16]. Furthermore, IL-8 works as a potent chemo-attractant for neutrophil that is the 
primary effector cell in COPD and severe asthma [1], and there are evidence establishing 
novel roles for IL-8 in human airway smooth muscle cell contraction and proliferation 
[16,17]. In the current work, we demonstrated that human monocyte/macrophage-derived 
MPs induced IL-8 release into the BSMC supernatant and such an effect was associated to an 
increase in the IL-8 gene transcription (Figure 8). These findings further underlie the 
importance of MPs as a key element of the interaction between mononuclear phagocyte 
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system and human airway smooth muscle, a dynamic triangle that could be critical in the 
pathophysiological network responsible for airway disease progression.  
The NF-κB pathway plays an important role in the TNF-α-induced pro-inflammatory 
phenotype in human airway smooth muscle cells [18]. We clearly showed that activation of 
the nuclear NF-κB pathway was the common molecular mechanism leading to the up-
regulation of PGE2 and IL-8 in MP-stimulated BSMC (Figure 8). In particular, after 
exposure of human BSMC to MPs, the released p50/p65 complex translocates into the 
nucleus and activated the transcription of NF-κB-regulated genes, including those coding for 
COX-2 and IL-8. Enhanced nuclear translocation of NF-κB by monocyte/macrophage-
derived MPs seems to be a hallmark of this membrane vesicle‟s type action because it was 
also observed in human lung epithelial cells [4] and in human monocytes [5] during 
paracrine and autocrine stimulation, respectively.  
Our findings demonstrated that MK could reverse the pro-inflammatory phenotype induced 
in BSMC by human monocyte-derived MPs. In particular, MK prevents nuclear translocation 
of NF-κB and mimics the effect of the selective inhibitor of NF-κB, Bay 11-7082, thus 
blocking IL-8 and PGE2 release and restoring salbutamol response in stimulated BSMC 
(Figure 8). Although the molecular mechanism underlying the inhibitory effect of CysLT1 
receptor antagonists on NF-kB activation remains unclear, several lines of evidence indicate 
that it is not mediated by antagonism of the CysLT1 receptor [19-22]. Therefore, together 
with the recognised ability to blocks the direct effect of cysLTs on bronchial smooth muscles 
during the early asthmatic response, the anti-inflammatory properties of MK might be 
useful, particularly in patients with persistent asthma who do not respond or became 
resistant to standard treatments. Furthermore, our results suggest that MK may have also an 
effective role in rheumatic diseases where MPs are an important driver of the inflammatory 
process [2]. 
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MP research and clinical analysis may be improved by using highly standardised protocols 
for MP isolation, detection and quantification and future research should be aimed at 
describing more fully the signal transduction pathways activated by MPs. The elucidation of 
the protein and lipid composition of monocyte/macrophage-derived MPs was beyond the 
purposes of the current study where our interest was primarily focused on using a 
standardised method for the induction of a rapid, complete and reproducible MPs release. 
With regards for this, the advantage of using the calcium ionophore instead of physiological 
activators was already discussed [3,5]. In this study and in previously published works [4,5], 
MPs was obtained by treating human monocytes isolated from the peripheral blood of 
healthy donors with A23187 at the concentration of 12 μM, which represents the EC50 mean 
value calculated from concentration-release experiments [3]. Characterization of MPs 
included the assessment of CD14+ and CD16+ elements percentage, tissue factor activity, 
phosphatidyl serine (PS) equivalents‟ concentration, and protein concentration in the 
samples. Specifically, we used 100 μl of supernatants from A23187-challenged monocytes 
corresponding to 10μg protein concentration (that ensured maximal effects) and to 2 nM 
equivalents of PS, in agreement with previously published works [5,23,24]. 
In conclusion, our findings provide evidence that MPs may play a role in the pathogenesis of 
airway inflammation by inducing a phenotype switch in human BSMC which consist in 
nuclear translocation of the p50/p65 complex, activation of NF-κB-regulated genes 
(including IL-8 and COX-2), induction of cytokine release (IL-8 and PGE2) and autocrine 
(PGE2-mediated) β2-adrenoceptor desensitization. Furthermore, MK may block this novel 
mechanism, which could be involved in the progression of chronic respiratory diseases. 
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Figure legends 
 
 
Figure 1.  Flow cytometry analysis of human monocytes and MPs from monocytes.  Figure 
shows a forward light scatter versus CD14+ (specific monocyte marker) and CD16+ (pro-
inflammatory marker) expression dot plot of unstimulated monocytes (A) and MPs 
generated from A23187-stimulated monocytes (B). This figure is representative of other four 
experiments. 
 
Figure 2. COX and β2-adrenoceptor gene expression (A), prostaglandin (PG)-E2 
release and β2-adrenoceptor function (B) in human BSMC upon overnight incubation 
with monocyte-derived microparticles (MPs). Data are reported as mean ± standard 
error of the mean (SEM). *p<0.05, **p<0.01, ***p<0.001 (n=5). 
 
Figure 3. Effects of indomethacin (non-selective COX inhibitor) (A) and NS398 
(selective COX-2 inhibitor) (B) on MP-induced β2-adrenoceptor desensitisation in 
human BSMC. Heterologous β2-adrenoceptor desensitization induced by exogenous 
PGE2 (C). Data are reported as mean ± standard error of the mean (SEM). *p<0.05, 
**p<0.01 (n=5). 
 
Figure 4. (A) RT-PCR images and densitometric analyses of interleukin (IL)-8 gene 
expression and (B) IL-8 release by MP-stimulated human BSMC. Data are reported as 
mean ± standard error of the mean (SEM). *p<0.05, ***p<0.001 (n=5). 
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Figure 5. Effects of the selective inhibitor of NF-κB, Bay 11-7082, at 1 μM for 24 h, on 
the release of IL-8 (A) and PGE2 (B) by MP-stimulated human BSMC. Data are reported 
as mean ± standard error of the mean (SEM). ***p<0.001 (n=5).  
 
Figure 6. Image and densitometric analysis of nuclear factor (NF)-κB activation in 
human BSMC stimulated with MPs in the presence or absence of montelukast 30 μM. 
Lanes 1-3: control, unstimulated BSMC; lanes 4-6: MP-challenged BSMC; lanes 7-9: 
montelukast (MK) + MPs. Specific antibodies against p65 and p50 subunits were used to 
confirm the specificity of the assay (see text for further details). Data are reported as 
mean ± standard error of the mean (SEM). ***p<0.001 (n=5).  
 
Figure 7. Effect of montelukast (MK) on MP-induced β2-adrenoceptor desensitisation 
(A) and IL-8 release (B) in human BSMC. Data are reported as mean ± standard error of 
the mean (SEM). *p<0.05, **p<0.01 (n=5).  
 
Figure 8. Overview of the possible molecular mechanisms involved in the pro-
inflammatory switch induced by monocyte-derived microparticles (MPs) in human 
bronchial smooth muscle cells (BSMC) and the protective effect of montelukast in this 
specific setting. 
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